Patents by Inventor Gregory A. Lazar

Gregory A. Lazar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fc Variants with Increased Affinity for FcyRIIc
    Publication number: 20190071512
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 7, 2019
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • CTLA4-Ig immunoadhesins
    Patent number: 10155800
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: December 18, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Fc variants with increased affinity for FcyRIIc
    Patent number: 10113001
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 30, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • OPTIMIZED Fc VARIANTS
    Publication number: 20180208668
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: December 12, 2017
    Publication date: July 26, 2018
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20180162946
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: September 19, 2017
    Publication date: June 14, 2018
    Inventors: Aaron CHAMBERLAIN, Bassil Dahiyat, John Desjarlais, Sher Bahadur Karki, Gregory Lazar
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20180134797
    Abstract: The present invention relates to anti-trans-ferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: November 18, 2015
    Publication date: May 17, 2018
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • ANTI-TRANSFERRIN RECEPTOR / ANTI-BACE1 MULTISPECIFIC ANTIBODIES AND METHODS OF USE
    Publication number: 20180057604
    Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 1, 2018
    Applicants: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan WU, Eric Krauland, Michael Feldhaus, Yin Zhang, Joy Yu Zuchero, Jessica Couch, Mark S Dennis, James A Ernst, Gregory A Lazar
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20180002433
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: June 5, 2017
    Publication date: January 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • Anti-transferrin receptor antibodies and methods of use
    Patent number: 9708406
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: July 18, 2017
    Assignee: GENENTECH, INC.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
    Publication number: 20170174757
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 22, 2017
    Inventors: Gregory Lazar, Bassil I. Dahiyat, Matthew J. Bernett
  • Optimized Fc variants
    Patent number: 9663582
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: May 30, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Optimized Fc variants
    Patent number: 9657106
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: May 23, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Antibodies with modified isoelectric points
    Patent number: 9605061
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 28, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Matthew J. Bernett
  • COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS
    Publication number: 20170058053
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Application
    Filed: September 28, 2016
    Publication date: March 2, 2017
    Inventors: Gregory Lazar, Gregory Moore
  • OPTIMIZED FC VARIANTS
    Publication number: 20160340436
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: July 8, 2014
    Publication date: November 24, 2016
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
    Patent number: 9493578
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: November 15, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Gregory L. Moore
  • Antibody variants with enhanced complement activity
    Patent number: 9475881
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: October 25, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • OPTIMIZED Fc VARIANTS
    Publication number: 20160304589
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: October 6, 2014
    Publication date: October 20, 2016
    Inventors: Gregory LAZAR, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20160264643
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 15, 2016
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • CTLA4-Ig immunoadhesins
    Patent number: 9371397
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: June 21, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett